Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about TIL, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Autologous Tumor Infiltrating Lymphocytes… | Advanced Cutaneous Melanoma | Phase 2 · NCT05050006 | Terminated |
| AXN-2510 | Solid Tumor, Adult | Phase 1 · NCT07159828 | Terminated |
| Anti-FOLR1 CoStAR-expressing Autologous… | Epithelial Ovarian Cancer | Phase 1 · NCT05397093 | Terminated |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
TIL holds $69.7M in cash and short-term investments (as of Jun 30, 2026) and burns about $3M/quarter from operations, an estimated runway of 69.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 40 · Elevated
As disclosed and defined in Note 10, the 2024 Loan has a scheduled maturity date in January 2027, with a total principal of $ 85.6 million, which is in excess of cash, cash equivalents, marketable securities and long-term investments on hand as of September 30, 2026, which management has concluded is an indicator of…10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TIL files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| BML Investment Partners, L.P. | 5%+ holder (13G) | 645,600 | 9.52% | 2025-12-31 |
Share count 6,781,976 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TIL and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →